1. Home
  2. AQB vs DRMA Comparison

AQB vs DRMA Comparison

Compare AQB & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AquaBounty Technologies Inc.

AQB

AquaBounty Technologies Inc.

HOLD

Current Price

$0.92

Market Cap

4.8M

Sector

N/A

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.08

Market Cap

4.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AQB
DRMA
Founded
1991
2014
Country
United States
United States
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
4.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
AQB
DRMA
Price
$0.92
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
23.4K
52.3K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
87.66
N/A
EPS
N/A
N/A
Revenue
$2,472,659.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.70
$1.10
52 Week High
$2.95
$7.02

Technical Indicators

Market Signals
Indicator
AQB
DRMA
Relative Strength Index (RSI) 37.63 30.74
Support Level $0.86 N/A
Resistance Level $1.02 $1.40
Average True Range (ATR) 0.04 0.09
MACD -0.01 -0.02
Stochastic Oscillator 4.64 24.49

Price Performance

Historical Comparison
AQB
DRMA

About AQB AquaBounty Technologies Inc.

AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: